Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 4:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 451 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Amyotrophic Lateral Sclerosis(ALS) Clear all
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose

NCT05136885
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
SLS-005, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 27, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dexpramipexole SAD/MAD Study

NCT01449578
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Dexpramipexole Placebo
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Sep 27, 2026, 4:57 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

ASSESS ALL ALS Study

NCT06578195
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 27, 2026, 4:57 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures

NCT05137665
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Movement Disorders, Degenerative Disorder, Motor Neuron Disease
Interventions
Not listed
Lead sponsor
Target ALS Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
10
States / cities
Phoenix, Arizona • San Diego, California • Georgetown, District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 27, 2026, 4:57 AM EDT
Completed No phase listed Observational

Validation of a New Device to Measure Neuromuscular Disease Progression

NCT00606918
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis & Other Neuromuscular Disorders
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2011 · Synced Sep 27, 2026, 4:57 AM EDT
Not listed Phase 1 Interventional

CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS

NCT03049046
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CC100, Placebos
Drug
Lead sponsor
Chemigen, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Sep 27, 2026, 4:57 AM EDT
Terminated No phase listed Observational Results available

Lower Extremity Fixation In Neuropathic Patients Study

NCT04607044
View directory record Official record
Conditions
Neuropathy, Charcot; Disease (Etiology)
Interventions
SALVATION™ EXTERNAL FIXATION
Device
Lead sponsor
Stryker Trauma and Extremities
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Trinity, Florida • West Chester, Pennsylvania • Sparta, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 27, 2026, 4:57 AM EDT
Completed Phase 1 Interventional

A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

NCT02655614
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
GDC-0134, Placebo, Rabeprazole, Midazolam, Caffeine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
San Francisco, California • Jacksonville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 27, 2026, 4:57 AM EDT
Completed Not applicable Interventional Results available

ALS and Airway Clearance (ALSAC) Therapy

NCT04947436
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Respiratory Muscle Weakness
Interventions
High Frequency Chest Wall Oscillation, Mechanical insufflation/exsufflation
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
21 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 27, 2026, 4:57 AM EDT
Completed Phase 2 Interventional

Creatine for the Treatment of Amyotrophic Lateral Sclerosis

NCT00070993
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
creatine monohydrate
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
21 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
6
States / cities
San Francisco, California • Chicago, Illinois • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2006 · Synced Sep 27, 2026, 4:57 AM EDT
Withdrawn Phase 2 Interventional

Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis

NCT03457753
View directory record Official record
Conditions
ALS
Interventions
Riluzole Oral Soluble Film
Drug
Lead sponsor
Aquestive Therapeutics
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2019 · Synced Sep 27, 2026, 4:57 AM EDT
Completed No phase listed Observational

Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population

NCT00718497
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
Interventions
Not listed
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 89 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 27, 2026, 4:57 AM EDT
Not listed Not applicable Interventional

EMPOWER Early Feasibility Study: Non-invasive BCI to Control a Wheelchair for People With Paralysis

NCT06169696
View directory record Official record
Conditions
Neurologic Disorder, Paralysis, Paralysis; Stroke, Amyotrophic Lateral Sclerosis, Spinal Cord Injuries, Cervical Spinal Cord Injury, Tetraplegic; Paralysis, Quadriplegia/Tetraplegia
Interventions
Intervention/Treatment
Device
Lead sponsor
Synaptrix Labs Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Sep 27, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)

NCT01884571
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Basiliximab, Methylprednisolone, Prednisone, Tacrolimus, Mycophenolate mofetil
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 27, 2026, 4:57 AM EDT
Active, not recruiting Phase 1 Interventional

Regulatory T Cells for Amyotrophic Lateral Sclerosis

NCT05695521
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CK0803, Excipient
Biological · Other
Lead sponsor
Cellenkos, Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Sep 27, 2026, 4:57 AM EDT
Withdrawn Phase 2 Interventional

A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS

NCT00561366
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo, Arimoclomol
Drug
Lead sponsor
CytRx
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
31
States / cities
Pacific Palisades, California • San Francisco, California • Denver, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Sep 27, 2026, 4:57 AM EDT
Not yet recruiting Phase 1 Interventional

Safety Study of XT-150 in Participants With ALS

NCT06704347
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
XT-150
Biological
Lead sponsor
Xalud Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
4
States / cities
Phoenix, Arizona • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 27, 2026, 4:57 AM EDT
Recruiting Not applicable Interventional

Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study

NCT06649955
View directory record Official record
Conditions
ALS - Amyotrophic Lateral Sclerosis
Interventions
Multi-site direct current stimulation (DCS)
Device
Lead sponsor
PathMaker Neurosystems Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 27, 2026, 4:57 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Therapy in Amyotrophic Lateral Sclerosis (ALS)

NCT00919555
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Pioglitazone and Tretinoin, Tretinoin and Pioglitazone HCL, Placebo
Drug
Lead sponsor
Phoenix Neurological Associates, LTD
Other
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 29, 2012 · Synced Sep 27, 2026, 4:57 AM EDT
No Longer Available No phase listed Expanded access

IC14 for ALS Patients Expanded Access

NCT04309604
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
IC14
Biological
Lead sponsor
Implicit Bioscience
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Sep 27, 2026, 4:57 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

NCT02794857
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
NP001, Placebo
Drug
Lead sponsor
Neuraltus Pharmaceuticals, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 27, 2026, 4:57 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

NCT05442775
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Reldesemtiv
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
21
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Sep 27, 2026, 4:57 AM EDT
Completed Not applicable Interventional

Early Feasibility Study of the MyoRegulator® for Treatment of ALS

NCT06165172
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
MyoRegulator®
Device
Lead sponsor
PathMaker Neurosystems Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 27, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis

NCT04245709
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Clenbuterol
Drug
Lead sponsor
Dwight Koeberl, M.D., Ph.D.
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2022 · Synced Sep 27, 2026, 4:57 AM EDT